Fresh analysis reveals that people who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain lost weight far faster than those who halt traditional diet and exercise programs.
Research printed in a prominent health publication points out that while obese individuals frequently drop a large proportion of their total mass while on the medication, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"People using such medications should be aware of the potential of rapid weight regain when the treatment concludes," stated lead investigator Dr. Susan Jebb.
That rate of regain suggests a return to original mass in about a year and a half.
Weighing Therapies
The research, which reviewed dozens of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with conventional dieting.
The team emphasize that people who lose weight through dieting generally have a less rapid weight regain—around 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Experts propose the mechanism of the drugs explains the heightened weight return.
These medications mimic a natural hormone called GLP-1, which controls appetite.
"Long-term administration of the hormone levels several times higher than normal may cause the system to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in appetite is unsuppressed, making binge eating a significant risk."
An Ongoing Issue?
The NHS recommend the jabs for individuals with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Many experts say that, given the likelihood of relapse, the treatment should be considered life-long.
This view is echoed by drug manufacturers, who say that the results "emphasize the persistent character of obesity," comparing it to managing conditions like hypertension.
Patient Experiences
Individuals who have discontinued the jabs describe a powerful return of hunger.
"I experienced a trigger that goes on and I was suddenly ravenous," recalled a patient.
This difficulty is compounded if individuals have not adopted lasting lifestyle or habit modifications during treatment.
Growing Interest
Survey data show that millions of adults in the UK have used these injections in the past year, with demand remaining high.
- Use is greater among females than men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians stress that while GLP-1 drugs are potent tools for weight loss, they are not a standalone fix and lasting health benefits relies on combined lifestyle changes.
